• Microglial Activation and Hippocampal Dysregulation in Alcoh

  2026-07-29

  This study uncovers how acute alcohol exposure increases seizure susceptibility by activating microglia in the hippocampus, which disrupts the balance of GABAergic and glutamatergic synaptic formation. The findings advance our understanding of neuroimmune mechanisms in alcohol-related seizure risk and offer a foundation for targeted translational research.

• Lipo3K Transfection Reagent: High-Efficiency for Tough Cell

  2026-07-29

  Lipo3K Transfection Reagent redefines nucleic acid delivery for challenging cell types by combining robust efficiency with minimized cytotoxicity. Its dual-component system and protocol flexibility empower advanced gene expression and RNA interference research, including difficult co-transfection scenarios.

• Pexidartinib (PLX3397) in Tumor Microenvironment Modulation

  2026-07-28

  Pexidartinib (PLX3397) enables highly selective CSF1R inhibition, empowering researchers to dissect macrophage roles in cancer progression and therapy resistance. This article guides experimental design, troubleshooting, and novel applications—anchored by recent breakthroughs in TAM-targeted modulation.

• Novobiocin: Unlocking Translational Value Beyond Antibacteri

  2026-07-28

  This article explores Novobiocin's mechanistic versatility, spanning DNA gyrase inhibition and Hsp90 targeting, and provides actionable insights for translational researchers. Drawing from recent synthetic and biological advances, it contextualizes Novobiocin’s multidomain potential, protocol optimization, and strategic considerations for resistance and antiparasitic research, while highlighting opportunities for innovation beyond traditional antibacterial workflows.

• Hydroxytyrosol: Advancing Antioxidant Workflows in Disease M

  2026-07-27

  Hydroxytyrosol, a phenolic antioxidant from APExBIO, empowers researchers to dissect oxidative stress and inflammation mechanisms with exceptional reproducibility. High purity, versatile solubility, and robust literature support make it ideal for cardiovascular, renal, and inflammation studies where data quality and workflow reliability are paramount.

• Phytochemical-Induced GSTM2 Activation Suppresses Bladder Ca

  2026-07-27

  The referenced study demonstrates that berberrubine, a natural isoquinoline alkaloid, potently upregulates glutathione S-transferase Mu 2 (GSTM2) in human bladder cancer cells through SP1 activation and DNA demethylation. This mechanism inhibits cancer cell proliferation, migration, and invasion, providing novel insight into GSTM2 as both a tumor suppressor and a therapeutic target.

• BMS-777607: Selective c-Met Inhibitor for Cancer and Platele

  2026-07-26

  BMS-777607 is a potent, selective c-Met inhibitor that demonstrates high specificity for MET kinase family members and is validated in cancer metastasis and stem cell-derived platelet protocols. The compound exhibits nanomolar IC50 values and robust in vivo efficacy, with notable selectivity and minimal toxicity. These properties make it a valuable tool in MET signaling pathway inhibition for research.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-07-25

  Schwartz's dissertation introduces a rigorous framework for distinguishing drug-induced cell death from proliferative arrest in cancer cell assays. This distinction enhances the interpretability and utility of in vitro drug response data, supporting more precise development and evaluation of apoptosis-targeted therapies.

• Bestatin Hydrochloride Advances Angiogenesis and Tumor Resea

  2026-07-24

  Bestatin hydrochloride (Ubenimex) is redefining experimental precision in angiogenesis inhibition and tumor biology research through potent, selective aminopeptidase inhibition. This article unpacks real-world workflows, troubleshooting insights, and reference-backed innovations to help scientists maximize reproducibility and interpretability in both cancer and neuroscience models.

• Cabozantinib XL184 in RCC: Protocols, Adaptation, and Optimi

  2026-07-24

  Cabozantinib (XL184) enables dynamic phosphoproteomic profiling in renal cell carcinoma models, uncovering adaptation patterns under chronic exposure. This guide delivers stepwise protocols, troubleshooting insights, and practical innovations drawn from cutting-edge studies to empower advanced kinase inhibitor research.

• Microglial Activation Drives Seizure Risk in Acute Alcohol E

  2026-07-23

  This study reveals that acute alcohol-induced seizures are mediated by microglial activation in the hippocampal CA1 region, which disrupts the balance between inhibitory and excitatory synapses. The findings provide mechanistic insights into neuroimmune modulation of seizure susceptibility and suggest targeted microglial interventions as a potential research direction.

• EZ Cap™ Cas9 mRNA (m1Ψ): Cap1-Engineered mRNA for Precision

  2026-07-23

  EZ Cap™ Cas9 mRNA (m1Ψ) enables high-fidelity CRISPR-Cas9 genome editing in mammalian cells by combining Cap1 capping, m1Ψ modification, and poly(A) tailing. This engineered mRNA enhances translation efficiency, reduces innate immune activation, and increases molecular stability, supporting advanced genome editing workflows.

• Next-Generation Cre Recombinase mRNA: Beyond Hepatic Barrier

  2026-07-22

  This article explores the mechanistic and strategic advances in Cre recombinase mRNA delivery, focusing on the integration of m1Ψ-modified, Cap 1-capped mRNA technology with virus-mimicking nanoparticles for efficient, low-immunogenicity extrahepatic gene editing. Drawing on recent breakthroughs, it offers actionable guidance for translational researchers seeking to overcome traditional delivery limitations.

• Angiotensin 1/2 (2-7) Peptide: Precision Tools for Vascular

  2026-07-22

  Angiotensin 1/2 (2-7) offers researchers a high-purity, versatile peptide for dissecting both vascular signaling and viral entry mechanisms. Its unique activity profile, robust solubility, and proven impact on spike–AXL interactions make it indispensable for cutting-edge blood pressure regulation and SARS-CoV-2 pathogenesis workflows.

• Dissecting Drug Response: In Vitro Metrics for Cancer Resear

  2026-07-21

  Schwartz's dissertation establishes that relative viability and fractional viability measure distinct aspects of cancer drug response, challenging the common practice of treating them interchangeably. By rigorously separating proliferative arrest from cell death in in vitro assays, the study refines interpretation of antitumor effects and offers a more nuanced foundation for translational oncology workflows.

15452 records 1/1031 page Next 12345 下5页 Last page